Combination therapy for newly diagnosed large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of three drugs for people recently diagnosed with a type of lymphoma called large B-cell lymphoma. The goal is to see if this combination is safe and effective, and it might offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with large B-cell lymphoma and have not had treatment yet.
- You have a moderate to high risk score (IPI 2-5) and are generally able to care for yourself (ECOG 0-2).
- You have at least one tumor that can be measured on a scan (larger than 1.5 cm).
- Your heart, liver, kidneys, and blood counts are within acceptable limits.
- You do not have lymphoma in the brain or spinal cord, and you have no serious infections or heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This study tests a combination of three drugs—pola, zanubrutinib, and lenalidomide plus prednisone—for people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this treatment can control the disease and improve outcomes.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Hear when a new Bispecific Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.